ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Washington, DC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Food Hypersensitivity
Hypersensitivity
Psoriasis
Allergic Rhinitis

Eczema trials near Washington, DC, USA:

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial (DISCOVER)

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema...

Active, not recruiting
Atopic Eczema
Moderate-to-Severe Atopic Dermatitis
Other: Topical emollient (moisturizer)
Drug: dupilumab

Phase 4

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Glenn Dale, Maryland, United States and 29 other locations

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Rockville, Maryland, United States and 41 other locations

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...

Active, not recruiting
Atopic Dermatitis
Drug: Placebo
Drug: ADX-914

Phase 2

Q32 Bio

Largo, Maryland, United States and 26 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

Washington, District of Columbia, United States and 179 other locations

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07264660
Drug: PF-07275315

Phase 2

Pfizer
Pfizer

Hunt Valley, Maryland, United States and 54 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Washington, District of Columbia, United States and 83 other locations

This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which co...

Enrolling
Atopic Dermatitis Eczema
Atopic Dermatitis
Other: Placebo
Drug: HY209GEL Active

Phase 2

Shaperon

Towson, Maryland, United States of America and 3 other locations

/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Rockville, Maryland, United States and 234 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Chevy Chase, Maryland, United States and 558 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Washington, District of Columbia, United States and 320 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems